AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38109916
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517 (aldosterone synthase inhibitor)
Trial: 38109984
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg QD
Trial: 38109984
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg QD
Trial: 38109984
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg QD
Trial: 38109984
Drug: Metoprolol 25
RxNorm normalized name: metoprolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 25 mg BID
Trial: 38110561
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/day for 21-28 days
Trial: 38110665
Drug: Cadonilimab 15
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 15 mg/kg Q3W plus anlotinib
Trial: 38110665
Drug: Cadonilimab 10
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10 mg/kg Q3W plus anlotinib
Trial: 38110790
Drug: Minzasolmin (UCB0599);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minzasolmin (UCB0599); orally administered small molecule inhibitor of ASYN misfolding; specific dosage and duration not mentioned.
Trial: 38110790
Drug: N-methyl labeled
RxNorm normalized name: N-methyl-pyrrolidone
DrugBank: Methyl pyrrolidone (DB12521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-methyl labeled PET tracer; specific dosage and duration not mentioned.
Trial: 38110885
Drug: Sofosbuvir and
RxNorm normalized name: sofosbuvir and ledipasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir and daclatasvir treatment
Trial: 38110885
Drug: Retesting patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retesting patients who completed treatment 12 months later
Trial: 38110901
Drug: HIP1601 (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIP1601 (dual delayed-release esomeprazole) 40 mg
Trial: 38110901
Drug: HGP1705 (delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGP1705 (delayed-release esomeprazole) 40 mg
Trial: 38112484
Drug: Semaglutide 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 0.4 mg
Trial: 38112645
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids used as an adjunct to antimicrobial therapy for herpetic keratitis
Trial: 38112645
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids used as an adjunct to antimicrobial therapy for bacterial keratitis
Trial: 38112645
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids for advanced bacterial corneal ulcers
Trial: 38112645
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids for fungal keratitis
Trial: 38112645
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids for acanthamoeba keratitis
Trial: 38112795
Drug: Generic pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic pomalidomide (4 mg daily on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22; 20 mg for patients aged > 75 years)
Trial: 38112795
Drug: Generic pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic pomalidomide plus low-dose dexamethasone
Trial: 38113022
Drug: Quantum Molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quantum Molecular Resonance (QMR) treatment, 4 sessions at 1-week intervals.
Trial: 38113446
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (2000 IU/day) in participants with <12 ng/mL and denied taking concurrent vitamin D
Trial: 38113446
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in participants with <12 ng/mL and denied taking concurrent vitamin D
Trial: 38113459
Drug: Parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group)
Trial: 38113459
Drug: Parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group)
Trial: 38113470
Drug: venetoclax-R2 (venetoclax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venetoclax-R2 (venetoclax 600 mg daily after ramp-up, lenalidomide 20 mg daily for days 1 to 21, rituximab 375 mg/m2 weekly for 4 weeks then every 8 weeks)
Trial: 38114518
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (combined)
Trial: 38114624
Drug: CFI-400945 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 at doses ranging from 64 mg/day to 128 mg/day
Trial: 38114718
Drug: Nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleos(t)ide analogue (NA) therapy cessation
Trial: 38114952
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation (AO) therapy
Trial: 38114958
Drug: Corega Ultra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corega Ultra denture fixative cream (GlaxoSmithKline)
Trial: 38115195
Drug: Nivolumab s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab s.c. 720, 960, or 1,200 mg
Trial: 38115195
Drug: Nivolumab i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab i.v. 3 mg/kg every 2 weeks
Trial: 38115195
Drug: Nivolumab i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab i.v. 10 mg/kg every 2 weeks
Trial: 38115208
Drug: Itacitinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (300 mg once daily) plus pembrolizumab (200 mg every 3 weeks)
Trial: 38115208
Drug: Parsaclisib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib (10 mg once daily in Part 1; 0.3 mg once daily in Part 2) plus pembrolizumab (200 mg every 3 weeks)
Trial: 38115209
Drug: Tozorakimab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozorakimab (subcutaneous or intravenous)
Trial: 38116137
Drug: Isotoxic dose
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotoxic dose escalation to 75 Gy in 30 fractions with concurrent bevacizumab (BEV)
Trial: 38116642
Drug: Daratumumab (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab (16 mg/kg) administered intravenously 16 times over 6 months
Trial: 38117500
Drug: Daily-delivered meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-delivered meals
Trial: 38117526
Drug: PF-07038124, 0.01%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07038124, 0.01%, topical ointment once daily for 6 weeks
Trial: 38117526
Drug: Vehicle, topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle, topical ointment once daily for 6 weeks
Trial: 38117527
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 3.75 mg
Trial: 38118022
Drug: Doxycycline PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline PEP (200 mg taken within 72 hours after condomless sex)
Trial: 38118249
Drug: PRT543 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT543 35 mg
Trial: 38118249
Drug: PRT543 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT543 45 mg
Trial: 38118406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CART-BCMA and CART-19
Trial: 38123789
Drug: Radium-223 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 + Endocrine Therapy (ET)
Trial: 38833643
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Endocrine Therapy (ET)
Trial: 38124098
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) iron treatment during early pregnancy
Trial: 38124098
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron treatment during early pregnancy
Trial: 38124112
Drug: Brazikumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazikumab (210 mg) administered subcutaneously every 4 weeks for 100 weeks
Trial: 38124481
Drug: ONC201 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 and paxalisib combination treatment
Trial: 38124508
Drug: Oral swabs
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral swabs collected from participants with early syphilis
Trial: 38124508
Drug: Oral shedding
RxNorm normalized name: Peroxy Shield Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral shedding in participants aged 18-29 years
Trial: 38124528
Drug: Rasagiline 1
RxNorm normalized name: rasagiline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 1 mg orally once daily
Trial: 38124551
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel (mean daily dose of 4 mg/day)
Trial: 38125301
Drug: Thyroid-stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid-stimulating hormone (TSH) levels
Trial: 38125672
Drug: Single-spin PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-spin PRP preparation (3,000rpm for 15 minutes)
Trial: 38125672
Drug: Double-spin PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-spin PRP preparation (first spinning at 1,500rpm for 6 minutes, continuing at 2,500rpm for 15 minutes)
Trial: 38125722
Drug: LTX-315 and
RxNorm normalized name: LTX-315
DrugBank: LTX-315 (DB12748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTX-315 and adoptive T-cell therapy
Trial: 38126083
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine, placebo, and cognitive behaviour therapy
Trial: 38126183
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate treatment
Trial: 38126709
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone 192 mg
Trial: 38126709
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone 384 mg
Trial: 38126709
Drug: NTX levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTX levels < 2 ng/mL
Trial: 38126764
Drug: Sapanisertib 3
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 3 or 4 mg daily together with metformin once to three times daily (500-1,500 mg).
Trial: 38127015
Drug: Inorganic nitrite
RxNorm normalized name: Nitrite
DrugBank: Nitrite (DB12529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic nitrite 40 mg 3 times daily
Trial: 38127212
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Trial: 38127508
Drug: FATIGUEWALK (FaW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FATIGUEWALK (FaW) plus treatment as usual (TAU)
Trial: 38127586
Drug: Emicizumab 3
RxNorm normalized name: Emicizumab 30 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks
Trial: 38128008
Drug: Blood specimens
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood specimens for SARS-CoV-2 antibody testing
Trial: 38128401
Drug: Caregiver emotional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver emotional reactions at mid-treatment
Trial: 38128401
Drug: Child PTS
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child PTS at mid-treatment
Trial: 38128402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavioral activation and mindfulness
Trial: 38128414
Drug: PepGNP-Dengue (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PepGNP-Dengue (low dose)
Trial: 38128414
Drug: PepGNP-Dengue (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PepGNP-Dengue (high dose)
Trial: 38128414
Drug: Vehicle-GNP (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle-GNP (low dose)
Trial: 38128414
Drug: Vehicle-GNP (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle-GNP (high dose)
Trial: 38128414
Drug: PepGNP-Dengue (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PepGNP-Dengue (both doses)
Trial: 38128460
Drug: Erythropoietin (EPO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO; 40,000 IU/ml)
Trial: 38128724
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (specific antibiotics not detailed)
Trial: 38129525
Drug: Berzosertib with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berzosertib with radiotherapy (RT) at six dose levels (highest dose 240 mg/m)
Trial: 38129731
Drug: Warmed IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed IgG 20% 0.4 g/kg
Trial: 38129731
Drug: Warmed IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed IgG 20% 1.0 g/kg
Trial: 38129731
Drug: Unwarmed IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unwarmed IgG 20% 1.0 g/kg
Trial: 38129910
Drug: Real sensorimotor
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Trial: 38129910
Drug: Sham sensorimotor
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Trial: 38130041
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg with SSRI/SNRI
Trial: 38130041
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg without SSRI/SNRI
Trial: 38130375
Drug: Duloxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine plus exercise (supervised treadmill walking 3 times weekly, duloxetine starting at 30 mg daily titrating to 60 mg daily)
Trial: 38130409
Drug: Zoliflodacin plus
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin plus doxycycline combination therapy
Trial: 38130645
Drug: QL0911 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL0911 (1 μg/kg subcutaneously once weekly for 24 weeks, adjusted to maintain platelet counts from 50 × 10^9/L to 200 × 10^9/L)
Trial: 38130645
Drug: Placebo (subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneously once weekly for 24 weeks)
Trial: 38131181
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (Exp-CBT)
Trial: 38131181
Drug: Traditional cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional cognitive behavior therapy (T-CBT)
Trial: 38131294
Drug: Neoadjuvant stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy
Trial: 38131617
Drug: Tofacitinib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib maintenance therapy
Trial: 38131621
Drug: famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famciclovir 500 mg twice daily for 12 weeks
Trial: 38131621
Drug: natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: natalizumab treatment (before famciclovir)
Trial: 38131628
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (including systemic therapy or chemoradiation)
Trial: 38133554
Drug: Oral selgantolimod
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selgantolimod 1.5 mg once weekly for 24 weeks
Trial: 38133554
Drug: Oral selgantolimod
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selgantolimod (3 mg or 1.5 mg)
Trial: 38133554
Drug: Oral selgantolimod
RxNorm normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selgantolimod (up to 3 mg)
Trial: 38133601
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAA) related HCV cure
Trial: 38133639
Drug: RSVPreF3 60
RxNorm normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 60 µg coadministered with dTpa
Trial: 38133639
Drug: RSVPreF3 120
RxNorm normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 120 µg coadministered with dTpa
Trial: 38133639
Drug: RSVPreF3 120
RxNorm normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 120 µg (second vaccination)
Trial: 38133639
Drug: RSVPreF3 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 (both doses)
Trial: 38133825
Drug: Malnutrition diagnosed
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malnutrition diagnosed using GLIM criteria at 7 weeks after treatment initiation
Trial: 38133914
Drug: Once-daily sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily sublingual 17-β estradiol
Trial: 38133914
Drug: Twice-daily sublingual
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily sublingual 17-β estradiol
Trial: 38133914
Drug: Transdermal 17-β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17-β estradiol
Trial: 38133914
Drug: Lipid panel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid panel, homeostatic model assessment for insulin resistance, coagulation factors II, IX, and XI, Von Willebrand factor, activated protein C resistance, protein C, and protein S
Trial: 38134037
Drug: automated directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: automated directly observed therapy-conditional economic incentive (aDOT-CEI) intervention
Trial: 38134305
Drug: Monitoring trachoma
RxNorm normalized name: Chlamydia trachomatis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring trachoma transmission with antibody data; estimated median IgG half-life of 3 years; seroreversion rate of 2.5 per 100 person-years (95% CI, 1.6-3.5)
Trial: 38134484
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block with 100 mg of ropivacaine
Trial: 38134484
Drug: Sciatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sciatic nerve block with 100 mg of ropivacaine
Trial: 38134948
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus cisplatin-based chemotherapy
Trial: 38134948
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin-based chemotherapy
Trial: 38135184
Drug: nab-paclitaxel +
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel + cisplatin + capecitabine as induction chemotherapy for three cycles
Trial: 38135187
Drug: SMART (Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART (Stereotactic MR-guided adaptive radiation therapy) delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions